Is Spain becoming a cost-effectiveness market for biopharma?

By Ciaran Cassidy, Snr Analyst Email: ccassidy@partners4access.com On the 25th of July, the AEMPS of Spain published the first Therapeutic Positioning Report (Informe de Posicionamiento Terapéutico, IPT) including both a clinical and a cost-effectiveness assessment.1 The Coordination Group of the National Health System (NHS) Drug Evaluation Network (REvalMED) evaluated Pfizer’s Talzenna® (talazoparib) as monotherapy for…